CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research
Seminars in Cancer Biology · 2025
DOI: 10.1016/j.semcancer.2025.07.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2025. Verfasst von Yanxi Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Gene Editing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Cooperation in Science and Technology.
Abstract (Originalsprache)
CRISPR/Cas9 technology has emerged as a powerful tool in pancreatic ductal adenocarcinoma cancer (PDAC) research, facilitating the study of genes involved in cell signaling pathways, proliferation, migration, invasion, and chemotherapy resistance. In this review, we discuss the evolution of CRISPR technologies from sophisticated editing techniques to broad screening methods, examine the utility of isogenic models and genetically engineered mouse models (GEMMs). We also explore how CRISPR/Cas9 screens can reveal immune-tumor cell interactions, highlighting the multifaceted role of this technology in PDAC research. Moreover, we emphasize the use of CRISPR technology in diagnostics for CAR-T cell therapies, where CRISPR/Cas9 enhances the precision of targeting malignant cells while minimizing off-tumor effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany.
- Dublin City University, School of Biotechnology, Dublin, Ireland.
- Faculty of sciences, Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen 91054, Germany.
- Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory for Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam, the Netherlands; Cancer Center Amsterdam,…
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
- Experimental Oncology Department, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Förderung
- European Cooperation in Science and Technology
Zitieren
APA
Lu, Y., Stoof, J., Tanoé, Y. R., Walsh, N., Bijlsma, M. F., Lei, H., Chen, T., Grahovac, J., Grützmann, R., & Pilarsky, C. (2025). CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2025.07.004
Vancouver
Lu Y, Stoof J, Tanoé YR, Walsh N, Bijlsma MF, Lei H, et al. CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. Seminars in Cancer Biology. 2025. doi:10.1016/j.semcancer.2025.07.004
BibTeX
@article{Lu2025,
author = {Lu, Yanxi and Stoof, Jojanneke and Tanoé, Yaba Rosette and Walsh, Naomi and Bijlsma, Maarten F and Lei, Huijun and Chen, Tianhui and Grahovac, Jelena and Grützmann, Robert and Pilarsky, Christian},
title = {CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research},
journal = {Seminars in Cancer Biology},
year = {2025},
doi = {10.1016/j.semcancer.2025.07.004}
}
EUVIMED